Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON54965
NL-OMON54965
Completed
Not Applicable

Single dose escalation study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 2413555 after oral dosing in healthy male participants in a randomized, single-blind, placebo-controlled, group-comparison design - A safety, absorption, elimination & activity study of BAY2413555

Bayer AG0 sites90 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Bayer AG
Enrollment
90
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Bayer AG

Eligibility Criteria

Inclusion Criteria

  • •\- Healthy male participants
  • •\- Age: 18 to 50 years of age (inclusive), at the time of signing the informed
  • •\- Race: White
  • •\- Body mass index (BMI) within the range of 18\-29\.9 kg/m2 (inclusive) at the
  • •time of screening.
  • •\- The informed consent must be signed before any study specific tests or
  • •procedures are done

Exclusion Criteria

  • •1\. Medical disorder, condition or history of such that would impair the
  • •participant\*s ability to take part in or complete this study in the opinion of
  • •the investigator
  • •2\. A history of relevant or ongoing diseases such as:
  • •\- respiratory tract: e.g. asthma, any airway obstruction
  • •\- central nervous system: e.g. seizures, cerebrovascular malformations (e.g.
  • •aneurysm), psychiatric or neurological disorders
  • •\- gastrointestinal tract: e.g. gallstones, any obstruction of the intestinum/
  • •intestinal glands (e.g. pancreas), peptic ulcer
  • •\- urinary tract: e.g. nephrolithiasis, any obstruction of the urinary passage

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A single ascending dose study to assess the safety, tolerability and pharmacokinetics of RO5428029 in healthy male subjectsHCVHepatitis C Virus infectioninfection of the liver10047438
NL-OMON34361Roche Nederland B.V.60
Unknown
Phase 1
Phase11 study of OPB-51602 in patients with hematologic malignanciesmultiple myeloma [MM], non-Hodgkin lymphoma [NHL], acute myeloid leukemia [AML], acute lymphoid leukemia [ALL], chronic myeloid leukemia [CML]
JPRN-jRCT2080221439Otsuka Pharmaceutical Co., Ltd.
Completed
Phase 1
First in human clinical study of a novel drug PTC607 to assess its safety and tolerability in healthy volunteersHuntington's DiseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
ACTRN12622001534774CTI Clinical Trial and Consulting Services Australia Pty Ltd.40
Not yet recruiting
Phase 1
First in human study of multiple doses of a novel drug PTC607 to assess its safety and tolerability in healthy participantsHuntington's DiseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
ACTRN12623001325695CTI Clinical Trial and Consulting Services Australia Pty Ltd24
Completed
Not Applicable
Ascending single dose study of the safety, tolerability, and pharmacokinetics of PRM-151 administered to healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF)
NL-OMON33156Centre for Human Drug Research32